Abstract:The transition of antimicrobial peptides (AMPs) from the laboratory to market has been severely hindered by their instability toward proteases in biological systems. In the present study, we synthesized derivatives of the cationic AMP Pep05 (KRLFKKLLKYLRKF) by substituting L-amino acid residues with D- and unnatural amino acids, such as D-lysine, D-arginine, L-2,4-diaminobutanoic acid (Dab), L-2,3-diaminopropionic acid (Dap), L-homoarginine, 4-aminobutanoic acid (Aib), and L-thienylalanine, and evaluated their antimicrobial activities, toxicities, and stabilities toward trypsin, plasma proteases, and secreted bacterial proteases. In addition to measuring changes in the concentration of the intact peptides, LC-MS was used to identify the degradation products of the modified AMPs in the presence of trypsin and plasma proteases to determine degradation pathways and examine whether the amino acid substitutions afforded improved proteolytic resistance. The results revealed that both D- and unnatural amino acids enhanced the stabilities of the peptides toward proteases. The derivative DP06, in which all of the L-lysine and L-arginine residues were replaced by D-amino acids, displayed remarkable stability and mild toxicity in vitro but only slight activity and severe toxicity in vivo, indicating a significant difference between the in vivo and in vitro results. Unexpectedly, we found that the incorporation of a single Aib residue at the N-terminus of compound UP09 afforded remarkably enhanced plasma stability and improved activity in vivo. Hence, this derivative may represent a candidate AMP for further optimization, providing a new strategy for the design of novel AMPs with improved bioavailability.

Progress in the development of bestatin analogues as aminopeptidases inhibitors.

Design, synthesis and biological evaluation of novel L-isoserine tripeptide derivatives as aminopeptidase N inhibitors.

New peptide deformylase inhibitors design, synthesis and pharmacokinetic assessment

Progress in the Development of Nonpeptidomimetic BACE 1 Inhibitors for Alzheimers Disease

Inhibition Profiling of Bestatin Against the Aminopeptidase B: in silico and in vitro Approach

LYP3, a new bestatin derivative for aminopeptidase N inhibition.

Design, Synthesis and Biological Evaluation of Novel Non-peptide Boronic Acid Derivatives As Proteasome Inhibitors

Design, Synthesis and Biological Evaluation of Novel Tripeptidyl Epoxyketone Derivatives Constructed from Β-Amino Acid As Proteasome Inhibitors.

Activatable Fluorescence and Bio/Chemiluminescence Probes for Aminopeptidases: From Design to Biomedical Applications

Design, Synthesis and Biological Evaluation of New Pyrazoline-Based Hydroxamic Acid Derivatives as Aminopeptidase N (APN) Inhibitors.

Design of potent aspartic protease inhibitors to treat various diseases

A Comprehensive Review on Current Advances in Peptide Drug Development and Design

Advances in the Development Ubiquitin-Specific Peptidase (USP) Inhibitors

Developments with investigating descriptors for antimicrobial AApeptides and their derivatives

Recent Advances of Aminopeptidases‐Responsive Small‐Molecular Probes for Bioimaging

Design, Synthesis, and QSAR Studies of Novel Lysine Derives As Amino-Peptidase N/CD13 Inhibitors.

Metabolism of Peptide Drugs and Strategies to Improve their Metabolic Stability

An Effective Modification Strategy to Build Multifunctional Peptides Based on a Trypsin Inhibitory Peptide of the Kunitz Family

Computational study of novel natural inhibitors targeting aminopeptidase N(CD13)

D- and Unnatural Amino Acid Substituted Antimicrobial Peptides With Improved Proteolytic Resistance and Their Proteolytic Degradation Characteristics

Recent progress of protein kinase inhibitors derived from marine peptides for developing anticancer agents